Guidelines for 10 mg Vitamin K Injection Administration

Administration Technique

• Administer a 10 mg dose of vitamin K intravenously by slow infusion over 30 minutes, never exceeding 1 mg per minute; rapid IV push can precipitate anaphylactic reactions that may lead to cardiac arrest. 1, 2

• Dilute the 10 mg dose in preservative‑free 0.9 % sodium chloride, 5 % dextrose, or a combination of both before infusion. (implicit in the infusion protocol) 1, 2

Safety Risks

• Anaphylactic reactions to IV vitamin K occur at a rate of approximately 3 per 100,000 doses; the reaction is non‑IgE mediated and is attributed to the polyoxyethylated castor oil solubilizer, presenting with cardiac arrest, severe hypotension, arrhythmias, dyspnea, and bronchospasm. 2

• Never exceed a total dose of 10 mg; higher doses are associated with a pro‑thrombotic state and can induce warfarin resistance lasting up to one week. 2

Indications

Life‑Threatening Bleeding

• For immediate reversal of life‑threatening bleeding, give 10 mg IV vitamin K concurrently with 4‑factor prothrombin complex concentrate (PCC) at 25–50 U/kg. 1, 2

• Co‑administration is required because factor VII in PCC has a half‑life of about 6 hours, necessitating vitamin K–driven synthesis of endogenous vitamin‑K‑dependent clotting factors. 2

Major Non‑Life‑Threatening Bleeding

• A 5–10 mg IV vitamin K dose infused slowly over 30 minutes is appropriate for major bleeding without hemodynamic instability. 1

Severe Over‑Anticoagulation Without Bleeding

• When INR > 10 in the absence of bleeding, a 5–10 mg dose may be given, but oral administration is preferred to avoid the anaphylaxis risk associated with the IV route. 2

Dosing Limits

• Do not exceed 10 mg of vitamin K in most clinical scenarios; doses above this threshold increase thrombotic risk and may cause prolonged warfarin resistance. 2

Monitoring & Thrombosis Risk

• Re‑check INR 15–60 minutes after PCC administration (when given together) to assess the degree of correction. (protocol derived from the co‑administration recommendation) 1, 2

• Continue regular INR monitoring over the subsequent week, as a minority of patients require more than one week to clear warfarin and may need additional vitamin K. 2

• Initiate thromboprophylaxis as early as feasible after bleeding control because PCC use raises the risk of both venous and arterial thrombosis during recovery. 2

Common Pitfalls to Avoid

• Avoid rapid IV push of vitamin K; this method dramatically increases the risk of anaphylaxis. 1, 2

• Do not use the subcutaneous route for a 10 mg dose; absorption is unpredictable and the FDA label recommends IV or IM administration. (guideline statement; no citation)

• Do not rely on vitamin K alone for reversal of life‑threatening bleeding, as its effect is delayed by several hours; combine with PCC for immediate correction. (supported by co‑administration guidance) 1, 2

Vitamin K Injection Guidelines

Life-Threatening or Major Bleeding

• For patients with serious bleeding and elevated INR, administer 5-10 mg IV vitamin K by slow infusion over 30 minutes, combined with 4-factor prothrombin complex concentrate (PCC) 25-50 U/kg IV for immediate reversal, as recommended by the American College of Cardiology 3, 4
• PCC achieves INR correction within 5-15 minutes, while vitamin K alone takes hours, making combination therapy essential for emergent situations, with a strength of evidence level of high 3, 4
• The dosing algorithm for PCC based on INR is: 25 U/kg if INR 2-4, 35 U/kg if INR 4-6, and 50 U/kg if INR >6, according to the American Heart Association 3

Emergency Surgery Requiring Rapid Reversal

• For patients on warfarin requiring emergency surgery, immediately administer 4-factor PCC 25-50 U/kg IV plus vitamin K 5-10 mg by slow IV infusion over 30 minutes, targeting INR <1.5, as recommended by the American College of Chest Physicians 3, 4
• This combination achieves surgical hemostasis within 15 minutes compared to hours with fresh frozen plasma (FFP), with a strength of evidence level of moderate 3

Severe Over-Anticoagulation Without Active Bleeding

• For INR >10 without bleeding, administer 5 mg oral vitamin K (preferred route) or 5-10 mg IV vitamin K if oral route is unavailable, as the risk of spontaneous major bleeding is 3.9% at 90 days, according to the American College of Cardiology 3, 4, 5
• Oral administration is preferred for non-emergency situations due to lower risk of anaphylactoid reactions (3 per 100,000 IV doses), with a strength of evidence level of high 3, 4

Critical Safety Considerations and Pitfalls

• Never exceed 10 mg vitamin K in most clinical situations, as higher doses create a prothrombotic state and cause warfarin resistance lasting up to one week, as warned by the American Heart Association 3, 4, 5
• High-dose vitamin K may require heparin bridging when warfarin needs to be resumed, with a strength of evidence level of moderate 4, 5
• Anaphylactic reactions to IV vitamin K occur via a non-IgE mechanism, possibly due to the polyoxyethylated castor oil solubilizer, and can result in cardiac arrest, severe hypotension, and bronchospasm, with a strength of evidence level of high 3, 4

When Injectable Vitamin K is NOT Indicated

• For INR 4.5-10 without bleeding, vitamin K is NOT routinely recommended—simply withhold warfarin and monitor serial INR determinations, as recommended by the American College of Cardiology 3, 5
• Randomized trials show vitamin K accelerates INR normalization but does not reduce major bleeding rates (2% with vitamin K vs 0.8% without), with a strength of evidence level of moderate 3
• Add oral vitamin K 1-2.5 mg only if high bleeding risk factors exist: age >65-75 years, history of bleeding, concomitant antiplatelet drugs, renal failure, or alcohol use, according to the American Heart Association 3, 5